RPTX - Repare Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.74
+0.60 (+2.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close29.14
Open29.71
Bid29.38 x 1000
Ask29.57 x 900
Day's Range29.14 - 29.95
52 Week Range28.20 - 34.00
Volume90,040
Avg. Volume756,210
Market Cap1.091B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Barrons.com

    Leaf Group, Forma Therapeutics See Activist Action

    Oak Investment Partners disclosed a large stake in digital-content provider Leaf Group. Forma Therapeutics said it owns more than nine million shares of biopharmaceutical firm Forma.

  • How He Made $2.8M Trading Stocks Part-Time At Home

    How He Made $2.8M Trading Stocks Part-Time At Home

    Kyle Dennis took a leap of faith and decided to invest his savings of $15K in the stock market — $2.8M later, he owes his success to these strategies

  • Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    Business Wire

    Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

    Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing of its previously announced upsized initial public offering of 12,650,000 of its common shares, including the exercise in full of the underwriters’ option to purchase up to an additional 1,650,000 common shares, at a public offering price of $20.00 per share. The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, were $253.0 million. All of the common shares were offered by Repare.

  • Business Wire

    Repare Therapeutics Announces Pricing of Upsized Initial Public Offering

    Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of its upsized initial public offering of 11,000,000 of its common shares at a public offering price of $20.00 per share. The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, are expected to be approximately $220.0 million. All of the common shares are being offered by Repare. In addition, Repare has granted the underwriters a 30-day option to purchase up to 1,650,000 additional common shares at the initial public offering price, less the underwriting commissions.

  • Man Who Predicted Rise of AMZN Has New Prediction

    Man Who Predicted Rise of AMZN Has New Prediction

    He called bottom of stocks in '09, and recommended AMZN before it soared an extraordinary 1,800%. Now he has a surprising new prediction for 2020.